Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Organ Transplant - Pediatric Clinical Trials

A listing of Organ Transplant - Pediatric medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (4) clinical trials

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disorder

PRIMARY OBJECTIVE: I. To determine the feasibility of treating pediatric and young adult solid organ transplant recipients who have newly diagnosed, relapsed or refractory Epstein-Barr virus (EBV)-positive CD20-positive post-transplant lymphoproliferative disease (PTLD) with a novel T-cell therapeutic, allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes (third party latent membrane protein [(LMP]-)]-specific T cells), in …

Phase

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia

Patients are randomized to 1 of 4 arms. ARM A: Patients undergo total-body irradiation (TBI) twice daily (BID) on days -10 to -7, and receive thiotepa intravenously (IV) over 4 hours on days -6 and -5, fludarabine IV over 30 minutes on days -6 to -2, tacrolimus IV continuously starting …

Phase

Propylene Glycol-Free Melphalan HCl (EVOMELA ) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

OVERVIEW Elderly and infirm patients with hematological malignancies often cannot undergo allogeneic hematopoietic cell transplantation (HCT) because of high-toxicity rates and nonrelapse mortality (NRM) associated with higher-intensity conditioning allografts. Reduced-intensity conditioning (RIC) transplantation has emerged as an attractive alternative for these populations. FLUDARABINE/MELPHALAN. In RIC, fludarabine is often used as …

Phase

A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in adult patients awaiting kidney transplantation. For Groups 1 and 2, adult CMV-seronegative (-) patients awaiting kidney transplant from a CMV-seropositive (+) living donor will be enrolled according to treatment intent with …

Phase